Global leader in human and environmental health enhances knowledge management technology portfolio with two strategic acquisitions
WALTHAM, MA – PerkinElmer, Inc. (NYSE: PKI), a global leader focused on the health and safety of people and the environment, today announced that it has signed a definitive agreement to acquire CambridgeSoft Corporation, and has completed the purchase of ArtusLabs, Inc. These acquisitions will enhance the Company’s focus on knowledge management in laboratory settings by expanding its informatics and software offerings, enabling customers to rapidly access and share enterprise-wide data for faster, more informed scientific decisions.
"The ability to integrate scientific tools and informatics is becoming increasingly critical for our customers as they look to drive productivity and speed tt o market," said Robert Friel, chief executive officer and chairman, PerkinElmer, Inc. "CambridgeSoft brings strong customer relationships and excellent organizational capability, along with market leading products in both desktop and enterprise-wide software. ArtusLabs provides us with innovative technology enabling enhanced access to scientific knowledge, and is highly complementary to CambridgeSoft's informatics solutions."
He added, "These acquisitions combined with our existing offerings, particularly our OneSource® laboratory asset management services, make us uniquely qualii fied to enable highly efficient laboratory environments and increased scientific productivity."
Based in Cambridge, Massachusetts, CambridgeSoft is a leading provider of discovery, collaboration, and knowledge enterprise solutions, scientific databases and professional services. CambridgeSoft primarily services pharmaceutical, biotechnology and chemical industries with solutions that help customers create, analyze and communicate scientific data while improving the speed, quality, efficiency and predictability of research and development investments.
Based in the Research Triangle Park area, North Carolina, ArtusLabs offers the Ensemble® scientific knowledge platform, to accelerate research and development in the pharmaceutical, chemical, petrochemical and related industries. Ensemble integrates disparate data from customers’ legacy Electronic Laboratory Notebooks (ELN) and informatics systems and databases, maximizing the value of an organization’s scientific intellectual capital.
For the full year 2011, CambridgeSoft and ArtusLabs anticipate aggregate revenues of approximately $65 million and the initial aggregate cash purchase price for these companies is approximately $220 million, plus potential additional contingent consideration of up to $15 million. The Company anticipates these transactions to be dilutive to 2011 GAAP earnings per share by approximately $0.13. This dilution to GAAP earnings per share is due primarily to adjustments related to purchase accounting. On a non-GAAP basis, which includes the adjustments in the attached reconciliation, the Company expects the transaction to be accretive to its adjusted earnings per share by approximately $0.04 for the balance of 2011.
The purchase of CambridgeSoft is expected to close in the second quarter, subject to customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
Use of Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release also contains a non-GAAP financial measure. The reasons that we use this measure, a reconciliation of this measure to the most directly comparable GAAP measure, and other information relating to this measure are included below.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products decline or do not grow as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or to successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products may expose us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) restrictions in our credit agreements; (19) our ability to realize the full value of our intangible assets; (20) significant fluctuations in our stock price; (21) reduction or elimination of dividends on our common stock; and (22) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
About CambridgeSoft Corporation
CambridgeSoft Corporation is a leading supplier of discovery, collaboration, and knowledge enterprise solutions, desktop software, scientific databases and professional services to the pharmaceutical, biotechnology, and chemical industries. The Company provides enterprise solutions, desktop software, scientific databases, and professional services for biotechnology, drug discovery and chemical research, including software, databases, and web sites which enable customers to create, analyze and communicate chemical, biological, and scientific information more effectively. Additional information is available at: http://www.cambridgesoft.com/
About ArtusLabs, Inc.
ArtusLabs, Inc. focuses on providing Web 2.0 enabled software solutions to the pharmaceutical and related industries. Its flagship product, Ensemble, blends social networking, collaboration, and refined scientific data mining to drive the research process, leading to faster time to market. ArtusLabs was founded by a proven team that was one of the pioneers of the Enterprise Electronic Lab Notebook marketplace. Additional information on ArtusLabs is available at: http://www.artuslabs.com
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.7 billion in 2010, has about 6,200 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
Adjusted Earnings Per Share
We use the term "adjusted earnings per share," or "adjusted EPS," to refer to GAAP earnings per share, excluding amortization of intangible assets, changes to the fair values assigned to contingent consideration, other costs related to business acquisitions, and including estimated revenue from contracts acquired in the CambridgeSoft and ArtusLabs acquisitions that will not be fully recognized due to business combination accounting rules. We believe that this non-GAAP measure, when taken together with our GAAP financial measures, allows us and our investors to analyze the costs of producing and selling our products and the performance of our internal investments in technology and our internal operating structure, to evaluate the long-term profitability trends of our core operations and to calculate the underlying value of the core business on a dilutive share basis, which is a key measure of the value of the Company used by our management and we believe used by investors as well. Adjusted earnings per share also facilitates the overall analysis of the value of the Company and the core measure of the success of our operating business model as compared to prior and future periods and relative comparisons to our peers. We exclude amortization of intangible assets, changes to the fair values assigned to contingent consideration, and other costs related to business acquisitions as these items do not represent what our management and what we believe our investors consider to be costs of producing our products, investments in technology and production, and costs to support our internal operating structure, which could result in overstating or understating to our investors the performance of our operations. We include estimated revenue from contracts acquired in the CambridgeSoft and ArtusLabs acquisitions that will not be fully recognized because our GAAP revenue for the periods subsequent to our acquisition do not reflect the full amount of revenue on these contracts that would have otherwise been recorded by CambridgeSoft and ArtusLabs. The non-GAAP adjustment is intended to reflect the full amount of such revenue. Our management and we believe our investors will use this adjustment as a measure of the ongoing performance of the CambridgeSoft and ArtusLabs businesses.
The non-GAAP financial measure described above is not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measure included in this press release may be different from, and therefore may not be comparable to, similar measures used by other companies.
David C. Francisco
Vice President, Investor Relations
Phone: (781) 663-5677
Stephanie R. Wasco
Vice President, Corporate Communications
Phone: (781) 663-5701
Corporate Public Relations Manager
Phone: (781) 663-5602
RESEARCH TRIANGLE PARK, N.C. (March 2, 2010) - ArtusLabs, Inc. (www.artuslabs.com), the leader in scientifically-aware data management systems, today announced that Icagen, Inc. (www.icagen.com), a leading biopharmaceutical company, has selected ArtusLabs’ Ensemble Electronic Lab Notebook™ (E2LN™) platform for use with its Chemistry organization.
Icagen will use the Ensemble Electronic Lab Notebook™ (E2LN™) platform to capture experimental data, results and decision support needs for Icagen’s medicinal chemistry and bio-analytical departments.
“We successfully used another ELN system for several years and decided to change to the Ensemble Electronic Lab Notebook. The ArtusLabs team made the transition easy. All of our chemistry legacy information was brought over to the new system seamlessly,” says Mark J. Suto, Ph.D., vice president of chemical and pharmaceutical sciences. Dr. Suto continues, “The Ensemble ELN is accessible via a Web browser and may provide opportunities for integration with other databases within Icagen. In addition, we are looking into using the Ensemble platform for other applications within chemistry such as bioanalytical data.”
Ensemble Electronic Lab Notebook™ (E2LN™) is the leading ELN technology for addressing the changing needs of the scientific workplace. ArtusLabs CEO, Robin Smith, says, “Icagen needed a system that was easy to deploy, easy to use and met its changing needs. Our E2LN is a second-generation product that supports a much broader base of scientists and enables scientific knowledge management across the organization. We’re excited to have been selected as Icagen’s new partner and look forward to continuing a rich relationship.”About ArtusLabs, Inc.
ArtusLabs is a business intelligence and document management company focused on providing Web 2.0 enabled software solutions to life science organizations. Its flagship product, Ensemble for Life Science™ blends social networking, collaboration, and refined scientific data mining to drive the research process, leading to faster time to market. Ensemble meets the regulatory and security requirements of the life science enterprise. The ArtusLabs team has been building software solutions for scientists for nearly a decade. Solutions such as Optical Structure Recognition™, Method Genius™, Research Decision Models, Sub Structure Search, Chemical Logistics, Ensemble Electronic Lab Notebook™ systems are examples of technologies developed by ArtusLabs and are in use by thousands of users around the globe. To learn more about ArtusLabs, Ensemble Electronic Lab Notebook™ (E2LN™), please visit: http://www.artuslabs.com/enotebook.htmlAbout Icagen, Inc.
Icagen is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads.
(919) 361-5050 ext. 16
RESEARCH TRIANGLE PARK, N.C. (February 3, 2010) - ArtusLabs, Inc. (www.artuslabs.com), today announced a partnership with the David H. Murdock Research Institute (DHMRI) (www.dhmri.org), to enable groundbreaking research at the North Carolina Research Campus (NCRC). Funded through a private grant by David H. Murdock, DHMRI is a 501©(3) organization has state of the art infrastructure and capabilities. DHMRI is a catalyst in the development of NCRC as a world class life sciences research campus advancing collaborations at the public-private interface with a scientific focus at the intersection of human health, nutrition, and agriculture. DHMRI’s partnership with ArtusLabs focuses on the use of the Ensemble Electronic Lab Notebook™ (E2LN™) platform.
DHMRI will use Ensemble Electronic Lab Notebook™ (E2LN™) to capture DHMRI’s experimental data, results and decision support needs for each laboratory. The Ensemble E2LN™ is a web deployed third generation ELN that blends high usability at the bench with collaboration technologies. This combination makes data and documents available for use for critical scientific decision making. The same deployment and platform will also support the disaster recovery needs of DHMRI.
Valerie Risch, CIO, DHMRI says, “Ensemble is an incredibly powerful system and is unique in that it can support both scientific and business processes. We are excited about working with ArtusLabs as we continue to explore other capabilities within the Ensemble platform.”
“Data management and analyses are critical components, necessary to ensure we meet the requirements of our diverse scientific customers. In a single platform, Ensemble provides a unified environment powering both the Electronic Lab Notebook as well as a diversified system for handling disaster recovery information and documentation. In addition, Ensemble ELN provides us a critical platform that will support the changing needs of our diverse set of labs from ‘omics to imaging:.” said Mark Burke, Director of Informatics of DHMRI.
“We couldn’t be more excited to partner with DHMRI. Their mission of supporting groundbreaking research using a trans-disciplinary, multi-institutional collaborative research perfectly aligns with the key differentiators of Ensemble Electronic Lab Notebook,” said Robin Smith, CEO of ArtusLabs.
To learn more, visit ArtusLabs Feb. 3 & 4, 2010 at the Molecular Tri-Conference in San Francisco, Calif., booth 220.About ArtusLabs, Inc.
ArtusLabs is a business intelligence and document management company focused on providing Web 2.0 enabled software solutions to life science organizations. Its flagship product, Ensemble for Life Science™ blends social networking, collaboration, and refined scientific data mining to drive the research process, leading to faster time to market. Ensemble meets the regulatory and security requirements of the life science enterprise. The ArtusLabs team has been building software solutions for scientists for nearly a decade. Solutions such as Optical Structure Recognition™, Method Genius™, Research Decision Models, Sub Structure Search, Chemical Logistics, Ensemble Electronic Lab Notebook™ systems are examples of technologies developed by ArtusLabs and are in use by thousands of users around the globe. www.artuslabs.comAbout David H. Murdock Research Institute
The David H. Murdock Research Institute (DHMRI) was established as a 501©(3) public charity to support groundbreaking research at the North Carolina Research Campus. DHMRI represents a bold and creative approach to promote collaboration at the public-private interface to integrate trans-disciplinary research between academia and industry. Funded through a private grant by David H. Murdock, the DHMRI hosts the world’s top talent and resources focused at the intersection of human health, agriculture and nutrition.. For more information, please go to http://www.dhmri.org.
RESEARCH TRIANGLE PARK, N.C. (January 25, 2010) - ArtusLabs, Inc. (www.artuslabs.com), announces the launch of Method Genius™, a system that allows analytical scientists to identify the best ways for separating compounds, developing methods and deconvoluting degradation products.
Analytical scientists employ an empirical process for finding the best methods for separating compounds. Method Genius utilizes the core algorithms of ArtusLabs’ platform technology, Ensemble for Life Science™ to connect methods, chemical structures and parameters. This data is typically scattered among various analytical, compound registry systems, and report data typically stored in SDMS systems. Method Genius takes this connectivity and ‘learns’ what is the most efficient process to employ and suggests to the scientist what to try.
“With Method Genius, analytical organizations have the tool they need to shortcut the current methodologies that go into finding the best method to separate compounds. We have seen a reduction of almost 80% in the time in takes for a scientist to find the best method and move on to their experiment,” said Robin Smith, CEO of ArtusLabs.
Mr. Smith continues, “Building on our innovative Electronic Lab Notebook (ELN), Method Genius is yet another example of how ArtusLabs employs the Ensemble for Life Science platform to index and aggregate instrument, compound and other unstructured data to allow for easy searching of critical scientific information. Method Genius solves a real need to slash the amount of time it takes an analytical scientist to find the best methods for separation.”
ArtusLabs’ approach is to blend customer driven needs with state of the art web enabled technologies, delivering a focused solution that solves pressing needs in the life science community. Method Genius represents the next generation in scientific analytical systems.
To learn more about Method Genius, visit ArtusLabs at the American Lab Automation Conference in Palm Springs, Calif. at the Palm Springs Convention Center, booth 435 or www.artuslabs.com/methodgenius.
About ArtusLabs, Inc.
ArtusLabs is a business intelligence and document management company focused on providing Web 2.0 enabled software solutions to life science organizations. Its flagship product, Ensemble for Life Science™ blends social networking, collaboration, and refined scientific data mining to drive the research process, leading to faster time to market. Using the best of Web 2.0 technologies, Ensemble meets the regulatory and security requirements of the life science enterprise. The ArtusLabs team has been building software solutions for scientists for nearly a decade. Solutions such as Optical Structure Recognition, Research Decision Models, Sub Structure Search, Chemical Logistics, Electronic Lab Notebook systems are examples of technologies developed by ArtusLabs and are in use by thousands of users around the globe.
ArtusLabs, Inc. Announces EnsembleDocs, the next generation in Document Management for the Enterprise
RESEARCH TRIANGLE PARK, N.C. (October 16, 2009) - ArtusLabs, Inc. (www.artuslabs.com), announces the launch of Ensemble Docs, a web-deployed system that addresses enterprise document management challenges.
Organizations struggle with how to capture information from the mass of documents created throughout the enterprise. EnsembleDocs sorts and provides the enterprise with the documents with the most meaning for the individual, the department and for the organization at large.
Created to address this constant problem of information overload in organizations, Ensemble Docs blends document management & archiving with deep content search and collaboration to provide instant access to information to increase the productivity of the work force.
“ArtusLabs’ experience in addressing complex software problems exposed us to this next big problem that organizations are facing, how to handle the increasing amounts of data and documents throughout the organization in a way that is easy to use and accessible by anyone,” said Robin Smith, CEO of ArtusLabs.
Mr. Smith continues, “EnsembleDocs challenges conventional document management systems. We start by assuming the system must be easy to use then we provide tools that drive secure collaboration around projects and documents provide organizations with the tools to meet the needs of the changing and evolving enterprise”.
ArtusLabs’ approach is to blend customer driven needs with state of the art Web 2.0 and Cloud Computing technologies, delivering a focused solution. A use-case driven technology, EnsembleDocs serves as the first document management solution on the market that combines deep search with collaboration and document management & archiving.
About ArtusLabs, Inc. ArtusLabs is a business intelligence and document management company focused on providing Web 2.0 enabled software solutions to enterprise organizations. Their flagship product, Ensemble, provides a window into company data that allows organizations to extract value from hidden assets and drive results by taking advantage of in-house intellectual capital. For more information, please visit :www.ensembledocs.com
SAN JOSE, CA & RESEARCH TRIANGLE PARK, NC (July 7, 2009) - ArtusLabs, Inc. (www.artuslabs.com), the leader in scientifically-aware data management systems, was profiled today on Apple.com (See Story Here). The profile highlights ArtusLabs commitment to rapidly adopting technologies that enable the organization to be nimble and instantaneously responsive to customer requests.
RESEARCH TRIANGLE PARK, N.C. (June 23, 2009) - ArtusLabs, Inc. (www.artuslabs.com), the leader in scientifically-aware data management systems, today announced that AzoRx, Inc. (www.azorx.com), a life-sciences project management firm with unique provider relationships for drug and device development., is the newest customer of their flagship product, Ensemble for Life Science™.
ArtusLabs will be exhibiting at Enterprise 2.0 (www.e2conf.com) in Boston, MA June 22-25, 2009.
“Ensemble helps us manage our internal information so that it is easy to find and use allowing us to drive our discovery and development efforts efficiently. Its life science components, the ability to search for documents using their embedded structure search tool, is invaluable for our organization that is so dependent on complex scientific data,” said David Zimmermann, co-founder and Managing Partner.
“Our customers also receive added value in that Ensemble is a web-deployed platform that is easy to use and helps us manage all of our documents and share them internally as well as externally. Our business is managed through effective external collaborations and we look forward to using Ensemble to help manage those relationships.”
AzoRx is using Ensemble to manage their company’s intellectual capital and ensure that it is accessible by everyone in the organization through an easy to use web interface. Dean Knuth, co-founder and Managing Partner said, “Training was simple. The ArtusLabs team addressed our questions and helped us get up and running in less than a day.”
“We’re excited to be able to help AzoRx with their scientific document management needs. We are impressed with the rate that AzoRx is growing and feel that both organizations will benefit from this working partnership,” said Robin Y. Smith, CEO and co-founder of ArtusLabs, Inc.
About ArtusLabs, Inc. ArtusLabs is paving the way in developing web-enabled technologies for the life science industry by striving to help their customers save time, reduce infrastructure costs, and increase organization’s information retention. ArtusLabs products and services are tuned to meet the needs of today’s enterprise organization. To learn more about ArtusLabs, Inc., please visit: http://www.artuslabs.com/enterprise2.html
About AzoRx, Inc. AzoRx provides strategic drug discovery and development services to pharmaceutical and biotechnology clients. AzoRx formed in 2007 to address a growing need among biotechnology and pharma companies utilizing a virtual or mixed-virtual model of business. To date the virtual model has met with limited success. The two causes for this failure are: 1. Failure to identify the best scientific talent, 2. Failure to identify a team of CROs invested in the success of the project. By leveraging their knowledge and contact base, AzoRx has succeeded in creating a unique talent pool of scientists that will effectively shepherd your program whether it be in early preclinical through late clinical development.
Media Contact: Amanda Brown ClearImage (for ArtusLabs, Inc.) (919) 863-2393 ext. 212 email@example.com
RESEARCH TRIANGLE PARK, N.C., May 19 /PRNewswire/ -- ArtusLabs, Inc. (www.artuslabs.com), the leader in scientifically-aware data management systems, today announced a collaborative license agreement with Incyte Corporation to address two prevalent industry problems. The first is to more effectively access and visualize scientific data and display the results in a web based interface. The second is a methodology and process for automatically harvesting and correlating analytical data from instruments and provide a web interface that allows scientists and group leaders to annotate and share those results with other scientists.
“Web based tools which access and visualize multi-dimensional research data allows organizations like Incyte to make faster and better decisions which, ultimately, drives the pace of our drug discovery process,” states, Andrew Combs, Executive Director, Incyte Corporation.
“We’re excited to work with the team at Incyte. They’re constantly challenging themselves and organizations like us to work on making the discovery process more efficient. It’s good to work on this new challenge with them,” says Robin Smith, CEO of ArtusLabs.
To address the second issue, utilizing their flagship product, Ensemble for Life Science™, ArtusLabs’ technology will enable the automatic integration of analytical data and its organization into collections which are then associated to on-going projects. “ArtusLabs has a unique product with Ensemble™. Working with analytical data from a variety of instruments and vendors has always been difficult to do in any scalable fashion. Ensemble™ will allow instant access to analytical data by anyone in an organization,” said, Andrew Combs, Executive Director, Incyte Corporation.
About ArtusLabs, Inc. ArtusLabs is paving the way in developing web-enabled technologies for the life science industry by striving to help their customers save time, reduce infrastructure costs, and increase organizations' information retention. ArtusLabs products and services are tuned to meet the needs of today’s scientific organization. To learn more about ArtusLabs, Inc., please visit: www.artuslabs.com.
ArtusLabs will be at booth 2006 at the Bio International Convention in Atlanta GA and sponsoring the Cloud Summit at Interop 2009 in Las Vegas in booth 750.
CONTACT: Amanda Brown of ClearImage, +1-919-863-2393 ext. 212, firstname.lastname@example.org, for ArtusLabs, Inc.
RESEARCH TRIANGLE PARK, N.C. (April 28, 2009) - ArtusLabs, Inc. (www.artuslabs.com), the leader in scientifically-aware data management systems, announces the launch of Ensemble Electronic Notebook . The team at ArtusLabs pioneered the Electronic Laboratory Notebook marketplace over 10 years ago at Synthematix. Now they’re back, and leading the market once again with an entirely new approach to Electronic Notebooks and data management solutions.
“We’re addressing the future needs of life science organizations, not only how to collect and create data but rather, how to best access and utilize that data to drive discovery. Our electronic notebook addresses not only the needs of specific scientific disciplines such as chemistry and biology, but also gives organizations the ability to capture any intellectual property or concept as an electronic record regardless of the originating system the document or record was created in. The Ensemble Electronic Notebook platform enables interdisciplinary collaboration knowledge sharing and data utilization across the organization,” said Robin Smith, CEO of ArtusLabs.
Mr. Smith continues, “We know there are competitors - we know there are options- however, this industry is lacking leadership. The process and business of scientific discovery is evolving before our eyes. Old modes of technology licensing and procurement also need to be challenged along with the technological aspects of a solution such as an electronic notebook. Ensemble Electronic Notebook addresses this need for flexibility and ArtusLabs is leading the marketplace with a fresh approach on technology deployment and implementation across the enterprise.”
ArtusLabs’ approach is to blend customer driven needs with state of the art Web 2.0 and Cloud Computing technologies to deliver a focused solution. A use-case driven technology, Ensemble Electronic Notebook serves as the first electronic notebook solution on the market that is flexible and delivers value across the entire enterprise.
The ArtusLabs’ Ensemble Electronic Notebook gives organizations a technology that can be deployed enterprise wide and provide specific solutions for multiple scientific disciplines.
About ArtusLabs, Inc.
With a wealth of experience and very close relationships with scientists around the globe, the team at ArtusLabs continues to build the best collaborative customer experience and technologies for researchers -- hands down. ArtusLabs is paving the way in developing Web 2.0 enabled software technologies blended with Cloud Computing software technologies for the life science industry. ArtusLabs strives to help their customers save time, reduce infrastructure costs, and increase organization’s information retention.
To learn more about ArtusLabs, Ensemble Electronic Notebook, please visit: www.artuslabs.com/enotebook.
ClearImage (for ArtusLabs, Inc.)
(919) 863-2393 ext. 212
RESEARCH TRIANGLE PARK, N.C. (March 11, 2009) - ArtusLabs, Inc. (www.artuslabs.com), the leader in scientifically-aware data management systems, and Viamet Pharmaceuticals, Inc. (www.viamet.com), a human therapeutic company focused on “best-in-class” metalloenzyme inhibitors, today announced the collaborative development of Metallobase™, Viamet Pharmaceuticals’ proprietary database of metalloenzymes and metalloenzyme inhibitors.
“ArtusLabs was the perfect choice to help us develop this critical system for our internal discovery efforts. Their in-house technical expertise in chemistry-oriented solutions and drug discovery awareness were the skills that we were looking for in a data management partner,” said Dr. Robert Schotzinger, President & CEO of Viamet Pharmaceuticals.
Utilizing their flagship product, Ensemble for Life Science™, ArtusLabs created a system that combines access of structured, database-driven data with unstructured data in the same environment. “To capture Viamet’s unstructured data, we utilized Ensemble’s powerful functionality as a module to the custom database developed for Viamet. This allowed us to rapidly and cost-effectively connect the structured search functionality of Viamet’s proprietary Metallobase™ with their unstructured data,” states Robin Smith, CEO of ArtusLabs. Ensemble is a system that blends data management, data mining, workplace collaboration and personal publication into one web-deployed system.
About ArtusLabs, Inc.
ArtusLabs is paving the way in developing web-enabled technologies for the life science industry by striving to help their customers save time, reduce infrastructure costs, and increase organization’s information retention. ArtusLabs products and services are tuned to meet the needs of today’s scientific organization. To learn more about ArtusLabs, Inc., please visit: www.artuslabs.com.
Robin Smith, CEO and Co-Founder of ArtusLabs will be speaking at the Southeast Venture Conference in Atlanta, GA March 11-12, 2009. To learn more, go to http://www.seventure.org/featured_cos.html.
About Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. has assembled a world-class team that comprises expertise in both bioinorganic chemistry and drug discovery and development. Viamet discovers and develops "best-in-class" small-molecule inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, the Metallophile™ Technology. www.viamet.com
ClearImage (for ArtusLabs, Inc.)
(919) 863-2393 ext. 212
Birmingham, Ala. and Research Triangle Park, N.C. - February 16, 2009 – DiscoveryBioMed, Inc. (www.discoverybiomed.com) announced today that it has partnered with ArtusLabs, Inc. (www.artuslabs.com) to identify best practices for managing significant amounts of image and numerical data. ArtusLabs’ flagship product, Ensemble for Life Science, will be the platform for managing DiscoveryBioMed’s scientific data.
“In addition to its own internal drug discovery initiatives, DBM is currently working on behalf of more than 15 active cell engineering and drug discovery clients.” DBM’s chief executive officer Erik Schwiebert explained. “Constant communication with the client and inclusion of the client in each small step of the process is essential to our services approach. In our view, Ensemble is a software program that brings added value to our client communications by adding a “social networking” flavor to communications between our client and our company principals for each drug discovery program. Bridging communication with effective data management ensures that we’re delivering high value, seamless research for our client base while at the same time allows us to also take advantage of Ensemble for our own discovery efforts.”
Tom Barr, chief operations officer and co-director, added, “One of the benefits of Ensemble is the ability to automatically bring machine data from our ‘robot’ into the system using the mass importer. Once set up, the data is up-to-date, accessible by the project team and organized into the appropriate folder...without me ever needing to touch it.”
The goal of this partnership will be to best practices in gathering, mining and processing, and tabulating large volumes of numerical data from light-based bioassays. Robin Smith, chief executive officer and co-founder of ArtusLabs, Inc. said, “We’re excited to be working with Dr. Schwiebert and his team. Deeply understanding the drug discovery process and the data it produces is critical for ArtusLabs. Biological-based information is often ignored in the scientific data management space. It can be made up of several document types, making it difficult to associate to one project. Ensemble was designed to solve this specific problem.”
About DiscoveryBioMed, Inc.
DiscoveryBioMed is a life sciences and biotechnology company that engages in R&D and services work in cell engineering and production and drug discovery. The company is located in Innovation Depot in Birmingham. Using physiologically relevant cell culture models preferably derived from normal and diseased adult human cells and tissues, it focuses on finding therapeutic compounds for a variety of human diseases. It also applies this custom human cell-based approach to its “fee-for-service” support to researchers in allied areas and currently serves clients both locally in Alabama as well as in 8 other states in the US currently.
About ArtusLabs, Inc.
ArtusLabs is paving the way in developing web-enabled technologies for the life science industry by striving to help their customers save time, reduce infrastructure costs, and increase organization’s information retention. ArtusLabs products and services are tuned to meet the needs of today’s scientific organization.
Please visit them at the Molecular Tri-Conference Exhibit, Booth #508, February 25-26, 2009 at the Moscone Convention Center, San Francisco, CA. To learn more, please visit: www.artuslabs.com.
ClearImage (for ArtusLabs)
(919) 863-2393 x212
Research Triangle Park, N.C and Indianapolis, Ind. - January 13, 2009 - ArtusLabs, Inc. (www.artuslabs.com), a provider of Web 2.0 software technologies and Semafore Pharmaceuticals (www.SemaforePharma.com) today announced the deployment of ArtusLabs’ Ensemble for Life Science™ platform to collect, search and share Semafore’s research & development documentation, information assets and critical intellectual property. Ensemble is an on demand software platform that brings the best of Web 2.0 technologies inside a private and secure business network.
“Ensemble is used primarily as an intellectual property management system. When we were preparing for due diligence processes, Ensemble greatly aided our efforts.” said Dr. Guillermo Morales, director of research and development for Semafore Pharmaceuticals. “We knew that Ensemble was worth the investment when, at a critical moment preparing for a due diligence process, there was key information urgently needed that could not be found. We turned to the Ensemble system. The very first search produced the exact result we were looking for. At the end, it took less time to find the information using Ensemble than it took for me to walk to the computer.”
Ensemble for Life Science™ is the first cloud computing solution that combines structurally aware enterprise search, chemically aware data management, and scientific collaboration into one system. Customers benefit from significant cost savings by reducing the time spent tracking down institutional knowledge, reproducing experiments and revisiting critical research decisions. Ensemble provides the employees at Semafore assurance that if they need to find scientific results, decisions or data, they’ll be able to find it quickly. “For me, in research, this is what I need to be able to spend more time focused on research and less effort on searching for the information I need,” added Dr. Morales.
Robin Smith, chief executive officer of ArtusLabs, Inc, said, “We are excited to work with Semafore to help them save time and manage their research data.”
“It is helpful that there is a software company out there that takes an innovative and efficient approach to scientific data management,” said Dr. Morales.
Dr. Joseph Garlich, Semafore’s chief scientific officer said, “From my point of view, ArtusLabs is the most innovative cost-effective scientific software provider in the market and has a capacity to really understand the research information retrieval problems we face everyday. For Semafore, being ahead of the curve is important…it helps us be more efficient in our research pursuits.”
About ArtusLabs, Inc.
ArtusLabs is paving the way in developing web-enabled technologies for the life science industry by striving to help their customers save time, reduce infrastructure costs, and increase organization’s information retention. ArtusLabs products and services are tuned to meet the needs of today’s scientific organization. These products include: Ensemble for Life Science, Ensemble Exchange (an online chemical sourcing database), chemical structure and reaction systems and toolkits developed to address very specific scientific technology needs. To learn more, please visit: www.artuslabs.com.
About Semafore Pharmaceuticals (www.SemaforePharma.com)
Semafore Pharmaceuticals is a clinical-stage drug discovery and development company focused on small molecule modulators of the PI3 kinase (PI3K) and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company’s focus-- Cancer. Semafore is one of the first biopharmaceutical companies to focus on both PI3K and PTEN and has successfully discovered and is developing a portfolio of drug candidates addressing these targets.
ArtusLabs, Inc., a leading provider of life science software tools
and data management solutions, has entered into a partnership with
Boston University's Center for Chemical Methodology and Library
Development (CMLD) to develop a way to standardize and expand the way
in which stereochemistry, and ultimately a three-dimensional
structures, are represented in the International Chemical Identifier
This project will influence chemical drawing and library management capabilities throughout the industry. Professor Scott Schaus at Boston University and Robin Smith, CEO of ArtusLabs, are jointly responsible for the inception and creation of this project. The research will be conducted at Boston University with collaborative input from ArtusLabs, Inc. "We're excited to bring our collective expertise together to expand an important open standard within the chemical industry," said Smith.
This is expected to be the first of many collaborative efforts between ArtusLabs, Inc. and academic institutions.
About ArtusLabs ArtusLabs is a technology company which is delivering scientific data management software. ArtusLabs was founded by the same proven team that formed Synthematix, the start-up that pioneered the Enterprise Electronic Lab Notebook marketplace Their flagship product is Ensemble for Life Sciences(TM). Visit them at the upcoming BIO 2008 June 17-20, at booth #5018. For more information visit www.artuslabs.com.
About Boston University, CMLD The Center for Chemical Methodology and Library Development at Boston University (CMLD-BU) is a center funded by the National Institute of General Medical Sciences (NIGMS) focused on the discovery of new methodologies to produce novel chemical libraries of unprecedented complexity for biological screening. The center seeks to create novel chemical libraries that uniquely probe three-dimensional space by employing stereochemical and positional variation within the molecular framework as diversity elements for library design.
ClearImage (for ArtusLabs) Amanda Brown, 919-863-2393 ext. 212; email@example.com
DURHAM, NC (April 8,2008) – ArtusLabs, a leading provider of life science software tools and data management solutions, today announced that the company has closed a $2.6 million round of venture financing. The Series A round was led by Hatteras Venture Partners and Southern Capitol Ventures.
ArtusLabs was founded by the award-winning management team that built Synthematix, the software solutions company that pioneered the Enterprise Electronic Lab Notebook marketplace and was eventually acquired by Symyx Technologies, Inc. (NASDAQ: SMMX) in 2005.
“We are thrilled to partner with Robin Smith and Brian Ballard to build the next generation research informatics company,” said Clay B. Thorp, General Partner, Hatteras Venture Partners. “Robin and Brian have assembled the same world-class team that we built with Synthematix. ArtusLabs is demonstrating the ability to generate rapid value by focusing this proven team of people on this tremendous pain-point in research informatics.”
ArtusLabs’s technology platform, Ensemble, has the potential to significantly reduce the research and development time a pharmaceutical or biotech organization spends discovering and developing novel therapeutic compounds. The company will use the funding round to invest and expand its technology platforms breadth of service, expand ArtusLabs marketing efforts and to fund new product development initiatives.
"A competitive marketplace has put intense pressure on life science companies to better streamline costs and increase operating efficiencies," said David Jones, a principal at Southern Capitol Ventures. "ArtusLabs has developed software solutions with the latest Web 2.0 technologies that directly address these challenges. The company's innovative technologies and outstanding management team makes it a very attractive addition to our portfolio."
“We are all very excited to be working again with this group of investors,” said Robin Y. Smith, CEO of ArtusLabs. “There is a growing pain-point in the life science industry when it comes to software solutions. From outdated platforms to obtuse licensing schemes, ArtusLabs was created to reinvent the way a life science enterprise uses its organizational data assets.”
About ArtusLabs ArtusLabs is a technology company which is delivering scientific data management software and services designed to enhance workplace collaboration and accelerate the rate of drug discovery. ArtusLabs was founded by the same proven team that formed Synthematix, the start-up that pioneered the Enterprise Electronic Lab Notebook marketplace. This leadership team has extensive expertise in processing, mining and managing complex scientific data and information generated from research activities. The company’s flagship product, Ensemble for Life Science, is a unique software solution for organizing data. It blends social networking, personal publication, and refined data mining to both internal and external research communication and management. For more information visit www.artuslabs.com.
About Hatteras Venture Partners Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to building successful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management. For more information, please visit www.hatterasvp.com.
About Southern Capitol Ventures Southern Capitol Ventures (SCV) is a Raleigh, North Carolina-based venture capital firm dedicated to helping outstanding entrepreneurs build market-leading companies. The firm is focused on providing capital and guidance to early-stage technology companies across the Southeast and Mid-Atlantic. Previous investments have included Art.com, DoublePositive, Batanga, ChannelAdvisor and Synthematix (acquired by Symyx NASDAQ:SMMX). For more information, please visit www.southerncapitolventures.com.